Retatrutide Phase 3 Data: Triple Agonist Cuts HbA1c, Weight in T2D
A phase 3 trial in The Lancet reports retatrutide cut HbA1c by 1.69–1.94 points and weight by up to 15.3% over 40 weeks, with no head-to-head comparison to Ozempic or Mounjaro.
A phase 3 trial in The Lancet reports retatrutide cut HbA1c by 1.69–1.94 points and weight by up to 15.3% over 40 weeks, with no head-to-head comparison to Ozempic or Mounjaro.